These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 21935931

  • 21. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
    Mancini M, Petta S, Martinelli G, Barbieri E, Santucci MA.
    J Cell Biochem; 2010 Feb 01; 109(2):320-8. PubMed ID: 20014066
    [Abstract] [Full Text] [Related]

  • 22. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism.
    Fernández de Mattos S, Essafi A, Soeiro I, Pietersen AM, Birkenkamp KU, Edwards CS, Martino A, Nelson BH, Francis JM, Jones MC, Brosens JJ, Coffer PJ, Lam EW.
    Mol Cell Biol; 2004 Nov 01; 24(22):10058-71. PubMed ID: 15509806
    [Abstract] [Full Text] [Related]

  • 23. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.
    De Carvalho DD, Binato R, Pereira WO, Leroy JM, Colassanti MD, Proto-Siqueira R, Bueno-Da-Silva AE, Zago MA, Zanichelli MA, Abdelhay E, Castro FA, Jacysyn JF, Amarante-Mendes GP.
    Oncogene; 2011 Jan 13; 30(2):223-33. PubMed ID: 20838376
    [Abstract] [Full Text] [Related]

  • 24. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.
    le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F, Gambacorti-Passerini C.
    J Natl Cancer Inst; 1999 Jan 20; 91(2):163-8. PubMed ID: 9923858
    [Abstract] [Full Text] [Related]

  • 25. Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells.
    Mancini M, Petta S, Iacobucci I, Salvestrini V, Barbieri E, Santucci MA.
    Cell Signal; 2010 Aug 20; 22(8):1247-53. PubMed ID: 20388540
    [Abstract] [Full Text] [Related]

  • 26. Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells.
    Zhang JH, He YL, Zhu R, Du W, Xiao JH.
    Tumour Biol; 2017 Jun 20; 39(6):1010428317713394. PubMed ID: 28639894
    [Abstract] [Full Text] [Related]

  • 27. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
    Elzinga BM, Nyhan MJ, Crowley LC, O'Donovan TR, Cahill MR, McKenna SL.
    Am J Hematol; 2013 Jun 20; 88(6):455-62. PubMed ID: 23440701
    [Abstract] [Full Text] [Related]

  • 28. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
    Ebos JM, Tran J, Master Z, Dumont D, Melo JV, Buchdunger E, Kerbel RS.
    Mol Cancer Res; 2002 Dec 20; 1(2):89-95. PubMed ID: 12496355
    [Abstract] [Full Text] [Related]

  • 29. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
    Grimaudo S, Meli M, Di Cristina A, Ferro A, Pipitone MR, Romagnoli R, Simoni D, Dieli F, Tolomeo M.
    Anticancer Drugs; 2013 Apr 20; 24(4):384-93. PubMed ID: 23370613
    [Abstract] [Full Text] [Related]

  • 30. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [Abstract] [Full Text] [Related]

  • 31. Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.
    Ju DS, Kim MJ, Bae JH, Song HS, Chung BS, Lee MK, Kang CD, Lee HS, Kim DW, Kim SH.
    Cancer Lett; 2007 Jul 08; 252(1):75-85. PubMed ID: 17223257
    [Abstract] [Full Text] [Related]

  • 32. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM, Jung KH, Kim SJ, Fang Z, Son MK, Yan HH, Lee H, Kim J, Shin S, Hong S, Hong SS.
    Cancer Lett; 2014 Jun 28; 348(1-2):50-60. PubMed ID: 24657654
    [Abstract] [Full Text] [Related]

  • 33. Janus kinase 2: a critical target in chronic myelogenous leukemia.
    Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB.
    Cancer Res; 2006 Jul 01; 66(13):6468-72. PubMed ID: 16818614
    [Abstract] [Full Text] [Related]

  • 34. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C, Krystal G, Varticovksi L, McKinstry R, Rahmani M, Dent P, Grant S.
    Cancer Res; 2002 Jan 01; 62(1):188-99. PubMed ID: 11782377
    [Abstract] [Full Text] [Related]

  • 35. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
    Wei YL, Liang Y, Xu L, Zhao XY.
    Anat Rec (Hoboken); 2009 Jul 01; 292(7):945-50. PubMed ID: 19548306
    [Abstract] [Full Text] [Related]

  • 36. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.
    Rahmani M, Reese E, Dai Y, Bauer C, Kramer LB, Huang M, Jove R, Dent P, Grant S.
    Mol Pharmacol; 2005 Apr 01; 67(4):1166-76. PubMed ID: 15625278
    [Abstract] [Full Text] [Related]

  • 37. Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.
    Zhao F, Mancuso A, Bui TV, Tong X, Gruber JJ, Swider CR, Sanchez PV, Lum JJ, Sayed N, Melo JV, Perl AE, Carroll M, Tuttle SW, Thompson CB.
    Oncogene; 2010 May 20; 29(20):2962-72. PubMed ID: 20228846
    [Abstract] [Full Text] [Related]

  • 38. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.
    Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, Roy DC, Valtieri M, Bruner-Klisovic R, Caligiuri MA, Bloomfield CD, Marcucci G, Perrotti D.
    Cancer Cell; 2005 Nov 20; 8(5):355-68. PubMed ID: 16286244
    [Abstract] [Full Text] [Related]

  • 39. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X, Zhao H, Li Y, Fan J, Sun Y, Wang S, Wang Z, Song P, Ju D.
    Autophagy; 2015 Nov 20; 11(2):355-72. PubMed ID: 25701353
    [Abstract] [Full Text] [Related]

  • 40. A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib.
    Mancini M, Leo E, Campi V, Castagnetti F, Zazzeroni L, Gugliotta G, Santucci MA, Martinelli G.
    Cell Signal; 2014 Aug 20; 26(8):1690-7. PubMed ID: 24747551
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.